Jerry Wan - Achieve Life Principal Officer
| ACHV Stock | USD 3.07 0.22 7.72% |
Insider
Jerry Wan is Principal Officer of Achieve Life Sciences
| Age | 43 |
| Phone | 604-210-2217 |
| Web | https://www.achievelifesciences.com |
Jerry Wan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jerry Wan against Achieve Life stock is an integral part of due diligence when investing in Achieve Life. Jerry Wan insider activity provides valuable insight into whether Achieve Life is net buyers or sellers over its current business cycle. Note, Achieve Life insiders must abide by specific rules, including filing SEC forms every time they buy or sell Achieve Life'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jerry Wan over three months ago Acquisition by Jerry Wan of 10500 shares of Achieve Life at 4.55 subject to Rule 16b-3 | ||
Jerry Wan over six months ago Acquisition by Jerry Wan of 5625 shares of Achieve Life subject to Rule 16b-3 |
Achieve Life Management Efficiency
The company has return on total asset (ROA) of (0.5409) % which means that it has lost $0.5409 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8604) %, meaning that it created substantial loss on money invested by shareholders. Achieve Life's management efficiency ratios could be used to measure how well Achieve Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Tomasz Kula | Tscan Therapeutics | N/A | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| Cedric MD | Apellis Pharmaceuticals | 53 | |
| MBA MD | Spero Therapeutics | 44 | |
| Jamie Moore | CytomX Therapeutics | N/A | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Gabriel BA | Immix Biopharma | 38 | |
| Timothy Mayer | NextCure | 60 | |
| MBA JD | Apellis Pharmaceuticals | 52 | |
| Bryan Mcmichael | Coherus BioSciences | 46 | |
| Stephen Elledge | Tscan Therapeutics | N/A | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Demetrios MD | Inozyme Pharma | N/A | |
| MBA MBA | Inozyme Pharma | 65 | |
| Solomon Langermann | NextCure | 65 | |
| AO FRACP | Assembly Biosciences | 65 | |
| Russell MS | Acumen Pharmaceuticals | 67 | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| Uri MD | Assembly Biosciences | 53 | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Joanne MD | Iteos Therapeutics | 52 | |
Management Performance
| Return On Equity | -1.86 | ||||
| Return On Asset | -0.54 |
Achieve Life Sciences Leadership Team
Elected by the shareholders, the Achieve Life's board of directors comprises two types of representatives: Achieve Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Achieve. The board's role is to monitor Achieve Life's management team and ensure that shareholders' interests are well served. Achieve Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Achieve Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cindy MD, Chief President | ||
| Jaime Xinos, Executive Commercial | ||
| Mark CPA, Chief Officer | ||
| Jerry Wan, Principal Officer | ||
| Anthony Clarke, President Chief Scientific Officer, Director | ||
| Richard Stewart, Chairman of the Board, CEO | ||
| John MBA, CEO Director | ||
| Thomas MBA, Executive Chairman | ||
| Craig Donnelly, Executive CMC | ||
| Mark Rubinstein, Head Affairs |
Achieve Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Achieve Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.86 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 64.95 M | ||||
| Shares Outstanding | 34.39 M | ||||
| Shares Owned By Insiders | 9.72 % | ||||
| Shares Owned By Institutions | 59.62 % | ||||
| Number Of Shares Shorted | 3.81 M | ||||
| Price To Earning | (0.03) X | ||||
| Price To Book | 3.12 X | ||||
| EBITDA | (26.73 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Achieve Stock Analysis
When running Achieve Life's price analysis, check to measure Achieve Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Achieve Life is operating at the current time. Most of Achieve Life's value examination focuses on studying past and present price action to predict the probability of Achieve Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Achieve Life's price. Additionally, you may evaluate how the addition of Achieve Life to your portfolios can decrease your overall portfolio volatility.